Nav: Home

PLOS Special Collection launch: Shaping novel TB treatments

March 22, 2019

To commemorate World TB Day, a Special Collection has been released by PLOS Medicine containing a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of tomorrow's optimal treatment for all forms of tuberculosis. This Special Collection is sponsored by the World Health Organization (WHO) and the French National Research Institute for Sustainable Development (IRD-France), and is co-ordinated by Dr Christian Lienhardt, Research Director at IRD-France and Dr Payam Nahid, Professor at University of California, San Francisco, USA.

The series is the outcome of a technical consultation organized by WHO on 11-13th March 2018 on "Advances in Clinical Trial Design for New TB Treatments to identify and outline, through expert consensus, the optimal characteristics of clinical trial designs to inform policy guidance for the development of new TB regimens. Building on the lessons learnt from a rich history of TB clinical trials, experts reviewed the various designs and tools currently used in the conduct of clinical trials and made a series of propositions to advance the field further, with a view to attaining the best quality data possible on new TB treatments. "To accelerate the development of new TB treatments it is essential to maximize sharing data and experiences and improve the way clinical trials are designed says Dr Matteo Zignol, Team Leader, Research for TB Elimination, Global TB Programme, WHO.

An iterative series of clinical trials undertaken in the 1970s and 1980s by the British Medical Research Council and the US Public Health Services established the modern day six-month regimen for drug susceptible TB. Since then, despite the arrival of two newly approved drugs in the market, progress to shortening duration of treatments for TB and improving tolerability of TB regimens has been unacceptably slow, with the treatment of drug-resistant TB still relying on a complex, poorly tolerated, combination of drugs administered for 9 to 20 months duration.

Development of new TB treatments will continue to be hampered by numerous challenges, ranging from the laboratory, with our reliance on mycobacteriology for endpoint definitions, to the field, wherein a clinical trials control arm needs to be selected and implemented in the face of rapidly changing policies. The most commonly touted challenge in TB therapeutics remains the absence of a surrogate marker that can be readily measured and that estimates with adequate certainty the anticipated treatment effect in late stage clinical development. New opportunities are emerging with the recent developments in PK/PD methodologies, novel clinical trial designs, new biomarkers, as well as recent advances in molecular diagnostics. A recently broadened and exciting pipeline of new candidate drugs compels us to revisit our current approaches to TB drug development, and based on the learnings of the last 50 years, to identify and seek consensus on best practices for future TB clinical trial designs. We are at an unprecedented cross point at which reflections on a rich history of clinical trials meet new advances in methodological methods and technologies to move forward research and approaches for new TB treatments, says Dr Christian Lienhardt.

The PLOS Medicine Special Collection launched on the 22nd March 2019 introduces a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of tomorrow's optimal treatment for all forms of TB.
In your coverage please use this URL to provide access to the launched Special Collection:

Image Credit: U.S. Centers for Disease Control and Prevention- Medical Illustrator, Public Health Image Library (PHIL) /

Image Caption: This illustration depicts a three-dimensional (3D) computer-generated image of a cluster of rod-shaped, drug-resistant, Mycobacterium tuberculosis bacteria, the pathogen responsible for causing the disease tuberculosis (TB). The artistic recreation was based upon scanning electron microscopic (SEM) imagery.

Competing Interests: The authors have declared that no competing interests exist.


Related Clinical Trials Articles:

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.
Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.
Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.
Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.
Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.
Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.
Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.
When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.
New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.
Telemedicine helps improve participation in clinical trials
Videos and creative uses of other visuals provide a novel way to obtain informed consent during clinical trials to improve participants' understanding and retention of trial information, according to a study by Nemours Children's Health System presented at the American Thoracic Society (ATS) Annual Conference.
More Clinical Trials News and Clinical Trials Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.